News

AbstractBackground: Advances in diagnostic criteria for transthyretin cardiac amyloidosis (ATTR-CM) and expanded insurance coverage for bone scintigraphy have…

AbstractObjectiveTo assess the neuropathic burden and quality-of-life impact in patients with wild-type transthyretin amyloidosis (wtATTR) using standardized…

Efficacy of acoramidis in transthyretin amyloid cardiomyopathy with and without atrial fibrillation: results from ATTRibute-CM. (Top) In this post hoc analysis of…

AbstractTransthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiac disease caused by the deposition of TTR in the heart. TTR is synthesized by…

At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…

AbstractTransthyretin amyloidosis (ATTR) is a multisystemic disorder associated with extracellular accumulation of misfolded transthyretin (TTR) protein forming…

Improved evaluation strategies are needed to recognize transthyretin cardiac amyloidosis (ATTR-CM) faster in patients presenting with heart failure (HF), especially…

AbstractFrontline therapy for systemic amyloid light chain (AL) amyloidosis has evolved significantly with the approval of daratumumab in combination with…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and tafamidis has proven efficacy in reducing mortality and…

An artificial intelligence (AI) model that analyzes the results of echocardiograms may help predict the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM…